De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Zynex Inkomsten in het verleden

Verleden criteriumcontroles 2/6

Zynex is de winst gegroeid met een gemiddeld jaarlijks percentage van 7.7%, terwijl de Medical Equipment industrie de winst jaarlijks groeide met 11.5%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 29.4% per jaar. Het rendement op eigen vermogen van Zynex is 18.4%, en het heeft een nettomarge van 3.1%.

Belangrijke informatie

7.7%

Groei van de winst

7.5%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie	8.9%
Inkomstengroei	29.4%
Rendement op eigen vermogen	18.4%
Nettomarge	3.1%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

With Zynex, Inc. (NASDAQ:ZYXI) It Looks Like You'll Get What You Pay For

Jul 31

Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88

May 03

Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts

Mar 03

Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system

Sep 21

These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely

Aug 02

Zynex Cures The Pain Of Its Shareholders: Q2 Results

Aug 01

Zynex: Upside Looks Well Priced In, Efficiency Headwinds Remain

Jul 25

Is Zynex, Inc. (NASDAQ:ZYXI) Trading At A 46% Discount?

Jul 12

Zynex June and Q2 orders hit all-time high, re-affirms Q2 and FY22 guidance

Jul 11

Is It Time To Consider Buying Zynex, Inc. (NASDAQ:ZYXI)?

Apr 13

Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly

Mar 23

Opbrengsten en kosten

Hoe Zynex geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:ZYXI Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven
30 Jun 24	194	6	144
31 Mar 24	189	8	140
31 Dec 23	184	10	136
30 Sep 23	186	16	130
30 Jun 23	177	17	122
31 Mar 23	169	17	114
31 Dec 22	158	17	104
30 Sep 22	150	18	96
30 Jun 22	143	20	89
31 Mar 22	137	19	84
31 Dec 21	130	17	81
30 Sep 21	116	10	77
30 Jun 21	101	5	72
31 Mar 21	89	5	63
31 Dec 20	80	9	53
30 Sep 20	69	10	43
30 Jun 20	60	11	35
31 Mar 20	52	10	30
31 Dec 19	45	9	26
30 Sep 19	41	9	23
30 Jun 19	37	10	19
31 Mar 19	34	10	17
31 Dec 18	32	10	16
30 Sep 18	31	10	14
30 Jun 18	29	10	13
31 Mar 18	27	9	11
31 Dec 17	23	7	10
30 Sep 17	18	4	8
30 Jun 17	15	3	8
31 Mar 17	13	1	8
31 Dec 16	13	0	9
30 Sep 16	13	-1	10
30 Jun 16	12	-2	10
31 Mar 16	12	-2	9
31 Dec 15	12	-3	9
30 Sep 15	11	-1	9
30 Jun 15	13	-1	10
31 Mar 15	11	-6	11
31 Dec 14	11	-6	11
30 Sep 14	12	-11	13
30 Jun 14	13	-12	15
31 Mar 14	17	-8	21
31 Dec 13	22	-7	21

Kwaliteitswinsten: ZYXI heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (3.1%) ZYXI } zijn lager dan vorig jaar (9.7%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van ZYXI is de afgelopen 5 jaar met 7.7% per jaar gegroeid.

Versnelling van de groei: De winstgroei ZYXI is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.

Winst versus industrie: ZYXI had het afgelopen jaar een negatieve winstgroei ( -65% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Medical Equipment ( 7.9% ).

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 18.4% ) van ZYXI wordt als laag beschouwd.

Zynex Inkomsten in het verleden

Verleden criteriumcontroles 2/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Zynex, Inc. to Report Q2, 2024 Results on Jul 25, 2024

First quarter 2024 earnings released: EPS: US$0 (vs US$0.043 in 1Q 2023)

Zynex, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Zynex, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Recent updates

Zynex, Inc. Obtains FDA Clearance for New Pain Management Device

Chief Operating Officer recently sold US$199k worth of stock

Investor sentiment deteriorates as stock falls 18%

Chief Financial Officer recently sold US$124k worth of stock

Consensus revenue estimates decrease by 11%

With Zynex, Inc. (NASDAQ:ZYXI) It Looks Like You'll Get What You Pay For

Price target decreased by 17% to US$17.50

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Zynex, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2024

Zynex, Inc. to Report Q2, 2024 Results on Jul 25, 2024

Zynex, Inc.(NasdaqGS:ZYXI) dropped from Russell 2000 Growth-Defensive Index

Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88

Zynex, Inc. Provides Earnings Guidance for the Second Quarter of 2024 and Reaffirms for the Full Year 2024

Price target increased by 8.1% to US$19.88

First quarter 2024 earnings released: EPS: US$0 (vs US$0.043 in 1Q 2023)

Zynex, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Zynex, Inc., Annual General Meeting, May 16, 2024

Consensus EPS estimates fall by 11%

Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts

Full year 2023 earnings: EPS and revenues miss analyst expectations

Zynex, Inc. Provides Earnings Guidance First Quarter and Full Year 2024

Zynex, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Zynex, Inc. Introduces New Products

Zynex, Inc. Receives FDA Clearance for its Next Generation NMES Device

Why Investors Shouldn't Be Surprised By Zynex, Inc.'s (NASDAQ:ZYXI) P/E

Zynex, Inc. Submits FDA Application for Its NMES Device

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $20 million worth of its shares.

Zynex, Inc. Provides Earnings Guidance for Fourth Quarter and Full Year of 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 24% to US$16.50

Investor sentiment deteriorates as stock falls 15%

Zynex, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Now 23% undervalued after recent price drop

Now 22% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Now 23% undervalued after recent price drop

Chief Financial Officer recently sold US$170k worth of stock

Chief Financial Officer notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 16%

Is Zynex (NASDAQ:ZYXI) Using Too Much Debt?

Second quarter 2023 earnings: EPS exceeds analyst expectations

Price target increased by 11% to US$24.00

Zynex, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Zynex, Inc. Confirms Earnings Guidance for the Second Quarter of 2023 and Reiterates Earnings Guidance for the Full Year 2023

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Investor sentiment improves as stock rises 30%

Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?

Full year 2022 earnings: EPS exceeds analyst expectations

Investor sentiment deteriorates as stock falls 24%

Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?

Zynex, Inc. Reaffirms Earnings Guidance for the Fourth Quarter and Full Year 2022

Now 25% undervalued

Insufficient new directors

Chief Financial Officer recently sold US$407k worth of stock

Investor sentiment improved over the past week

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Third quarter 2022 earnings: EPS exceeds analyst expectations

Zynex, Inc. Provides Revenue Guidance for the Fourth Quarter 2022

Zynex, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Zynex, Inc. Re-Iterates Earnings Guidance for the Full Year 2022

Short Squeeze Candidate With Low PEG Ratio: Zynex

Zynex, Inc. Begins Enrollments in Large-Scale Blood Loss Detection Clinical Trial with its Second-Generation Monitoring System, CM-1600

Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system

Zynex, Inc. Announces First Enrollments in Apheresis Donation Clinical Trial with Second Generation Fluid Monitoring System

These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely

Zynex Cures The Pain Of Its Shareholders: Q2 Results

Zynex, Inc. Provides Revenue Guidance for the Third Quarter of 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations